ArticleJournal of cancer research and clinical oncology2004
Tyrosine kinase receptor expression in thymomas.
Article in Journal of cancer research and clinical oncology, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 2 syntheses or guidelines pooled it, 85 citations in OpenAlex.
- Relationship of possible biomarkers with malignancy of thymic tumors: a meta-analysis.BMC cancer · 2020Pooled it
- [Policies and reporting guidelines for small biopsy specimens of mediastinal masses].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2014Guideline
- Imatinib mesylate in patients with WHO B3 thymomas and thymic carcinomas.Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2009Trial
- Current Clinical Paradigm and Therapeutic Advancements in Thymic Malignancies: A Narrative Review.Cancers · 2025Review
- Immunotherapy and Targeted Therapies Efficacy in Thymic Epithelial Tumors: A Systematic Review.Biomedicines · 2023Review
- An overview on the differential diagnostics of tumors of the anterior-superior mediastinum: the pathologist's perspective.Mediastinum (Hong Kong, China) · 2019Review
- A novel prognostic signature of seven genes for the prediction in patients with thymoma.Journal of cancer research and clinical oncology · 2019Article
- A rare highly aggressive tumour: lymphoepithelioma-like thymic carcinoma.BMJ case reports · 2017Article
- The enlightenments from ITMIG Consensus on WHO histological classification of thymoma and thymic carcinoma: refined definitions, histological criteria, and reporting.Journal of thoracic disease · 2016Review
- KRAS, EGFR, PDGFR-α, KIT and COX-2 status in carcinoma showing thymus-like elements (CASTLE).Diagnostic pathology · 2014Article
- Radiotherapy for thymic carcinoma: adjuvant, inductive, and definitive.Frontiers in oncology · 2014Review
- Successful Use of Erlotinib in Treating Recurrent Thymic Carcinoma: A Case Report.World journal of oncology · 2013Article
- Thymic epithelial tumours: from basic principles to individualised treatment strategies.European respiratory review : an official journal of the European Respiratory Society · 2013Review
- Anti-Apoptotic Signature in Thymic Squamous Cell Carcinomas - Functional Relevance of Anti-Apoptotic BIRC3 Expression in the Thymic Carcinoma Cell Line 1889c.Frontiers in oncology · 2013Article
- Long lasting efficacy of sorafenib in a heavily pretreated patient with thymic carcinoma.Targeted oncology · 2012Article
- Thymic malignancies: from clinical management to targeted therapies.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2011Review
- Targeted therapy for advanced thymic tumors.Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2010Review
- Expression and mutational status of c-kit in thymic epithelial tumors.Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2010Article
- Epidermal growth factor receptor, C-kit, and Her2/neu immunostaining in advanced or recurrent thymic epithelial neoplasms staged according to the 2004 World Health Organization in patients treated with octreotide and prednisone: an Eastern Cooperative Oncology Group study.Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2010Article
- Comprehensive genomic analysis reveals clinically relevant molecular distinctions between thymic carcinomas and thymomas.Clinical cancer research : an official journal of the American Association for Cancer Research · 2009Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposePromising new therapies for neoplasia include tyrosine kinase receptor antagonists. Tyrosine kinase oncogenes present an appealing anti-tumor drug target since they play an integral role in a variety of cellular responses including cell proliferation and differentiation. We previously demonstrated a high rate of epidermal growth factor receptor (EGFR) expression in advanced-stage thymic epithelial tumors. More recently, we have examined c-KIT (CD117) expression in a similar series of tumors.
methodsTumor from 35 patients seen at our institution for treatment of advanced-stage thymoma was available. Twenty thymomas and 15 thymic carcinomas were assessed for c-KIT expression. Tissue sections of tumor were stained immunohistochemically with anti-c-KIT (Oncogene). Either cytoplasmic or membrane staining was considered positive. Appropriate controls were performed. Positive staining for c-KIT was present in 12 tumors (11 thymic carcinomas and 1 thymoma).
resultsIn distinction to EGFR, c-KIT is expressed more commonly in thymic carcinomas (73% of carcinomas) than in thymoma (5% of thymomas).
conclusionsAn EGFR negative/c-KIT positive staining pattern is typical of thymic carcinoma, whereas thymomas are generally EGFR positive/c-KIT negative. Possible therapeutic implications of these observations remain to be determined.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.